ストックスクリーナーアプリを入手
4.31
2.33%
0.0981
アフターアワーズ：
4.31
前日終値:
$4.2119
開ける：
$4.23
24時間の取引高:
59,315
Relative Volume:
0.15
時価総額：
$126.91M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+22.44%
1か月 パフォーマンス:
-0.23%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$4.21
$4.40
1週間の範囲:
$3.4437
$4.40
52週間の値動き範囲:
$2.5701
$26.50
Turn Therapeutics Inc Stock (TTRX) Company Profile
名前
Turn Therapeutics Inc
セクター
電話
(818) 564-4011
住所
250 NORTH WESTLAKE BLVD., WESTLAKE VILLAGE
TTRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TTRX
Turn Therapeutics Inc
|
4.31 | 125.14M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Turn Therapeutics Inc (TTRX) 最新ニュース
Arthur Golden Increases Stake in Turn Therapeutics Inc with Rece - GuruFocus
Golden Arthur F buys Turn Therapeutics shares worth $33945 By Investing.com - Investing.com Nigeria
Golden Arthur F buys Turn Therapeutics shares worth $33945 - Investing.com
Turn Therapeutics Director Arthur F Golden Acquires 9,868 Shares - TradingView
Dir Golden Buys 9,868 ($33.9K) Of Turn Therapeutics Inc [TTRX] - TradingView
Insider Buying: Arthur Golden Acquires Additional Shares of Turn Therapeutics Inc (TTRX) - GuruFocus
Turn Therapeutics Director Arthur F. Golden Acquires 20,532 Shares - TradingView
Dir Golden Buys 20,532 ($58.9K) Of Turn Therapeutics Inc [TTRX] - TradingView
[Form 4] Turn Therapeutics Inc. Insider Trading Activity - Stock Titan
Turn Therapeutics Inc. Common Stock trading resumes - MSN
Zuraiz Chaudhary buys Turn Therapeutics (TTRX) shares worth $9,050 By Investing.com - Investing.com Nigeria
Zuraiz Chaudhary buys Turn Therapeutics (TTRX) shares worth $9,050 - Investing.com
Turn Therapeutics (TTRX) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat
Turn Therapeutics’ GX-03 Recognized for Dermatology Innovation - MSN
Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates - The Manila Times
Turn Therapeutics GX-03 Technology Named as One of Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment by Patient Care Online Magazine - MarketScreener
Turn Therapeutics (Nasdaq: TTRX) features Dr. Robert Redfield on trust in science - Stock Titan
Turn Therapeutics’ GX-03 Technology Named as One of 'Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine - The Manila Times
Turn (NASDAQ: TTRX) named among five novel eczema mechanisms by Patient Care Online - Stock Titan
Turn Therapeutics appoints Andrew Scott as VP of Corporate Communications - Investing.com Australia
Turn Therapeutics Appoints New VP of Communications - TipRanks
Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications - The Globe and Mail
Turn Therapeutics appoints Andrew Scott as VP of Corporate Communications By Investing.com - Investing.com South Africa
Turn Therapeutics Appoints Veteran Capital Markets - GlobeNewswire
Turn Therapeutics (NASDAQ: TTRX) names Andrew Scott VP of Corporate Communications; 30 years - Stock Titan
Turn Therapeutics launches webinar series for shareholder engagement - MSN
Turn Therapeutics Inc (TTRX) Stock News Today - TipRanks
Turn Therapeutics files to sell 7M shares off common stock for holders - MSN
TTRX News Today | Why did Turn Therapeutics stock drop today? - MarketBeat
Turn Therapeutics (TTRX) Stock Trends and Sentiment 2025 - MarketBeat
Turn Therapeutics (TTRX) Competitors and Alternatives 2025 - MarketBeat
Turn Therapeutics (TTRX) 10K Form and SEC Filings 2025 - MarketBeat
Turn Therapeutics signs license deal with surgical product supplier Medline - MSN
Turn Therapeutics partners with Medline for global supply agreement By Investing.com - Investing.com Australia
Turn Therapeutics Partners with Medline for Global Expansion - TipRanks
Turn Therapeutics (NASDAQ: TTRX) teams with Medline to commercialize PermaFusion products - Stock Titan
Turn Therapeutics (TTRX) Stock Price, News & Analysis - MarketBeat
Turn Therapeutics (NASDAQ:TTRX) Insider Purchases $65,715.60 in Stock - Defense World
Turn Therapeutics appoints Kester to board of directors - MSN
Form 424B5 Turn Therapeutics Inc. - StreetInsider
What is the current Price Target and Forecast for Turn Therapeutics Inc. (TTRX) - Zacks Investment Research
Should I buy Turn Therapeutics Inc. (TTRX) - Zacks Investment Research
Turn Therapeutics Inc (TTRX) 財務データ
Turn Therapeutics Inc (TTRX) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.44%
0.91%
大文字化:
|
ボリューム (24 時間):